Cellular and vaccine immunotherapy for multiple myeloma.
Hematology Am Soc Hematol Educ Program
; 2016(1): 521-527, 2016 Dec 02.
Article
em En
| MEDLINE
| ID: mdl-27913524
Allogeneic hematopoietic cell transplantation and donor lymphocyte infusion for multiple myeloma (MM) can induce graft-versus-myeloma immunity and long-term survivorship, but limited efficacy and associated toxicities have prevented its widespread use. Cellular immunotherapies and vaccines seek to induce more specific, reliable, and potent antimyeloma immune responses with less treatment-related risk than is possible with allogeneic transplantation. Advances in molecular biology, and basic and applied immunology, have led to promising approaches such as genetically engineered T cells with chimeric antigen receptors and T-cell receptors targeting myeloma-specific epitopes, vaccine primed ex vivo expanded autologous T cells, expanded marrow-infiltrating lymphocytes, and plasma cell/dendritic cell fusion vaccines. The addition of these emerging therapies to immunomodulatory drugs and inhibitors of programmed death-1 T-cell regulatory pathways are poised to improve outcome for our patients with myeloma.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas Anticâncer
/
Transferência Adotiva
/
Terapia Baseada em Transplante de Células e Tecidos
/
Fatores Imunológicos
/
Mieloma Múltiplo
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Hematology Am Soc Hematol Educ Program
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2016
Tipo de documento:
Article
País de publicação:
Estados Unidos